Overall, while inflammation is a consistent feature of HD pathology, conflicting findings highlight the need for well-designed longitudinal studies with stratified patient cohorts to validate the clinical use of inflammatory biomarkers like IL-6, YKL-40, and IL-17 in HD diagnosis. Here, CHI3L1 is linked to Huntington disease.